We’re proud to share that our Senior Licensing Associate, Megan Reed PhD, MBA has been selected as a 2025 recipient of the Susan Riley Keyes Memorial Fellowship from the AUTM
Newly granted patent: U.S. Patent No. 12,268,674 B2, “Mi-2β Inhibitor as an Immunotherapy Agent” What’s the problem? Immune checkpoint therapies, such as anti-PD-1 antibodies (e.g. Keytruda, Opdivo), have transformed cancer
BioVentures will be present at the Translational Research Institute (TRI) Research Expo 2025, taking place Wednesday, September 10, from 4:00 to 6:00 p.m. CDT at the Reynolds Institute on Aging,
Stefanie Kennon-McGill, Ph.D., Senior Program Manager at BioVentures LLC, will be the featured speaker at 2 p.m. Wednesday, August 27, for the Health Sciences Entrepreneurship Grand Rounds. The topic will be “Leveraging
Curious how an idea becomes a protected invention at UAMS? At BioVentures, we guide innovators through every step, from disclosure to patent decisions and market strategy. Here’s how the process
BioVentures supported University of Arkansas for Medical Sciences (UAMS) first-year medical students this summer through the Partnership in Cancer Research (PCAR) program. Over eight weeks, participants worked in multidisciplinary teams
Newly granted patent: U.S. Patent No. 12,281,171 B2, “Periostin Antibodies and Methods of Using the Same” What’s the problem? Some cancers create a unique “signal” by adding a rare sugar modification
BioVentures’ 2025 interns modernized core data systems and explored how UAMS innovations reach the market, bridging science and business. BioVentures is wrapping up its 2025 Internship Program on August 1,
Every breakthrough at the University of Arkansas for Medical Sciences (UAMS) starts the same way: a question, an experiment, a spark of insight. Yet fewer than 10% of academic discoveries
BioVentures recently took part in the 2025 Arkansas Commercialization Retreat, held June 2–4 at the Winthrop Rockefeller Institute. Organized by the University of Arkansas’ Office of Entrepreneurship and Innovation, this
BioVentures LLC has adopted Tradespace, an AI-driven platform built specifically for technology-transfer offices, to streamline invention disclosures and commercialization efforts across UAMS. Beginning this month, all UAMS inventors will submit
BioVentures hosted its first annual Innovation Week from May 12–15, 2025, bringing together researchers, startups, industry partners, and investors to explore the future of biomedical innovation at UAMS. The event featured a
DISCLAIMER: Information on this website is not legal advice and should not be relied on as such. The law can change and the information contained on this site may be outdated, so you should always consult an attorney regarding your specific issues in view of the current state of the law. Please contact our team at bioventures@uams.edu if you have any questions and we can help determine a course of action.
